NEW YORK (Reuters Health) – Vedolizumab does not appear to worsen COVID-19 outcomes in patients with inflammatory bowel disease (IBD), according to data from the Surveillance of Coronavirus Under Research Exclusion for IBD (SECURE-IBD) registry. “At the onset of COVID-19, there was a significant concern about what effects the virus might have on patients with